Agoracom Blog Home

Posts Tagged ‘medical Marijuana’

Namaste $N.ca Announces Signing of Consulting Agreement With O Cannabis We Stand On Guard For Thee Corporation $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by Er at 8:20 AM on Tuesday, December 12th, 2017
  • O Cannabis will provide patient consultation services to Namaste’s wholly owned subsidiary, NamasteMD Inc
  • O Cannabis will also be offering a select range of Namaste’s vaporizer hardware in their online platform.

VANCOUVER, British Columbia, Dec. 12, 2017 (GLOBE NEWSWIRE) — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(OTCQB:NXTTF)(FRANKFURT:M5BQ) is pleased to announce that further to its December 5, 2017 announcement: NAMASTE ANNOUNCES NON-BINDING LETTER OF INTENT WITH O CANNABIS CLINIC FOR MANAGEMENT SERVICES, the Company has signed a Services Agreement (the “Agreement”) with O Cannabis We Stand On Guard For Thee Corporation (“O Cannabis”), whereby O Cannabis will provide patient consultation services to Namaste’s wholly owned subsidiary, NamasteMD Inc. (“NamasteMD”). Pursuant to the Agreement, O Cannabis will provide management services to NamasteMD that will include patient consultations, education, strain recommendations and medical document issuance to qualified patients under the guidance of nurse practitioners. In addition to these services, O Cannabis will also be offering a select range of Namaste’s vaporizer hardware in their online platform.

Terms of the Agreement
Under the terms of the Agreement, O Cannabis’ management team will be responsible for the general operation of NamasteMD’s platform and will provide the following services:

  • Patient Qualification
  • Patient Onboarding
  • Education
  • Recommendations (strains and dosages)
  • Follow-up Care
  • Medical Documents
  • Self-titration Training
  • Maintaining 75% patient retention rates

In return for these services, Namaste will pay O Cannabis as follows:

  • CAD $60 for each patient approval, being a patient consultation resulting in the issuance of a prescription for medical cannabis
  • 50% of the net profit for “platinum” packages, as outlined in the Agreement
  • 5% of the gross revenue collected for patients where medical cannabis is sourced from local licensed producers
  • 10% of the gross revenue collected for patients where medical cannabis is sourced from international licensed producers
  • 15% of the gross revenue collected through the sale of Namaste’s vaporizers and cannabis ancillary products, which O Cannabis will add to its website
  • The issuance of 15,000 common share stock options to the O Cannabis management team

Execution of this Agreement represents a major milestone in the expansion of the NamasteMD platform into medical cannabis sales using the Company’s innovative telemedicine application, and will provide an incredibly efficient platform for patient consultations and medical documentation issuance. NamasteMD customers will have the ability to connect to Namaste’s e-commerce platform through Namaste’s wholly owned subsidiary, Cannmart Inc. (“CannMart”), which will provide patients with an online marketplace for medical cannabis products, including strains sourced from both domestic and international licensed producers. CannMart is a late stage applicant for a “Sales Only License” under the Canadian Access to Cannabis for Medical Purposes Regulations (“ACMPR”) program. Namaste’s goal is to become Canada’s leading medical cannabis online retailer by leveraging its existing consumer base, along with utilizing its advanced expertise in e-commerce. In doing so, Namaste believes it can successfully convert and on-board patients at an accelerated growth rate and offer the best quality of care for its patients. Namaste believes that with its aggressive growth strategy and the implementation of NamasteMD, it will be able to accumulate a minimum of 18,200 patients within the first calendar year of operations. This figure is based on Namaste’s current site traffic of 1,000 unique visitors per day with a 5% conversion rate, which would generate 350 patients per week. Namaste expects each patient acquisition to cost on average $60.00 per patient, based on the terms of the Agreement, which is currently lower than any industry standard for medical patients.

About O Cannabis
O Cannabis offers affordable medical cannabis telemedicine appointments to patients across Canada, allowing timely access to quality medicine in remote and under-serviced regions; from Yukon to Newfoundland and everywhere in between. O Cannabis has built a name for themselves by offering unparalleled patient education and industry leading follow up care. O Cannabis patients report their appreciation for the easy and fun telemedicine experience, O Cannabis’ streamlined approach to medical document issuance and the exceptional care patients receive at each step of their medical cannabis journey.

About NamasteMD
NamasteMD is an innovative application that connects patients with medical practitioners through a secure video conference call and incorporates industry-leading facial recognition technology, including instant age and identity verification using data feeds linked to federal databases.  The O Cannabis management team is a highly trained group of medical professionals that offer industry leading care for their patients. Through the NamasteMD platform, patients will be offered a variety of packages that will include both free and paid options. Once a patient receives a medical document, they will have access to purchase directly from CannMart’s medical cannabis marketplace, once CannMart receives its “Sales Only License”. The Company expects the full launch of NamasteMD, including the app for both Apple and Android platforms, to be in operation and accepting patients as soon as December 15, 2017.

Management Commentary
Morgan Toombs, President and CEO of O Cannabis comments: “We are delighted that Namaste has recognized O Cannabis’ expertise within the medical cannabis industry.  Our forte is offering unparalleled education and follow-up care to medical cannabis patients so they can safely navigate the confusing landscape. Our team is honoured to be able to help Namaste’s patient demographic and bring much needed access to qualified Canadians so they can benefit from medical cannabis as a treatment option. We look forward to providing our exceptional care to Namaste’s patients throughout the course of their medical cannabis journey.”

Sean Dollinger, President and CEO of Namaste comments: “We are very proud to be working with such a professional group of people. O Cannabis’ team is dedicated to offering the best possible service and support for patients. This Agreement represents a major milestone for Namaste in launching what we believe to be the most innovative platform for patient acquisitions that the Canadian medical cannabis market has seen. We are looking forward to working with O Cannabis in revolutionizing the way patients connect with doctors and nurse practitioners and will look to create the fastest growing database of patients in the country. Thanks to O Cannabis and their team as well as Namaste’s management team in bringing this opportunity to life. We are very excited about the future!”

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastevapes.com

Further information on the Company and its products can be accessed through the links below:
www.namastetechnologies.com
www.namastevaporizers.com
www.namastevaporizers.co.uk
www.everyonedoesit.com
www.everyonedoesit.co.uk

Namaste $N.ca Featured on Capital Ideas TV, Cannabis Special Episode! $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:52 AM on Friday, December 1st, 2017

 

Nlogo

Capital Ideas Media publisher Mark Bunting examines the growth potential and trends in the global cannabis sector using some great charts and stats.

Mark speaks to Namaste Technologies co-founder and CEO, Sean Dollinger, about how the company plans to capitalize on its world-leading position as the number one seller of vaporizers. The stock has surged lately but is still undervalued.

Marijuana Company of America $MCAO Provides Update on 30,000 Sq. Ft. Cultivation Facilty in Washington State $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:47 AM on Tuesday, November 28th, 2017

15233 mcoa

  • Announced that it’s joint venture partner, Bougainville Ventures, Inc., initiated construction on a 30,000 square foot cultivation facility in Washington state
  • Delivery of the first pre-designed greenhouses, with full tracking and reporting protocols, is expected to be completed this week for the I-502 facility

Escondido, California–(November 28, 2017) – MARIJUANA COMPANY OF AMERICA INC. (OTC: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that it’s joint venture partner, Bougainville Ventures, Inc., initiated construction on a 30,000 square foot cultivation facility in Washington state. The delivery of the first pre-designed greenhouses, with full tracking and reporting protocols, is expected to be completed this week for the I-502 facility. The site will eventually consist of 6 greenhouses providing a total of 30,000 sq. ft., of cultivation area. The construction is expected to be completed in February of 2018.

This one acre footprint of greenhouse is anticipated to be a technologically advanced and predominantly automated cannabis production facility. The Company also has an option to purchase additional contiguous acreage and so may choose to expand its leasehold in the area. Bougainville Ventures, Inc. anticipates the facility to be capable of producing in excess of 12,000 lbs. of high quality cannabis annually once the cultivation area is fully built out. The location of the new facility provides access to transportation, industrial infrastructure, power, water, gas, and courier services.

Donald Steinberg, CEO of the Company, observed: “We have raised eight hundred thousand dollars and have issued fifteen million shares of the Company’s common stock, per the revised agreement with Bougainville Ventures, Inc. The tenant is in the process of obtaining approval of plans and issuance of permits from Okanogan County and Washington State Liquor Control Board (WSLCB) to authorize construction on the first phase of the project. This transaction enables the joint venture to install 4 of the 6 design automated greenhouse systems.” Mr. Steinberg also added “The attainable goal for the joint venture is to deliver the finished project early in Q1 2018 so that our tenant can begin producing revenues shortly thereafter.”

Additional details on this specific project will be announced in the coming weeks. MCOA continues to be a company pursuing aggrotech, cannabis, and advanced organic greenhouse farming assets. Meanwhile, for more information on this project including images of the jobsite, please visit: http://marijuanacompanyofamerica.com/

About Bougainville Ventures, Inc.
Bougainville Venture Inc. is in the core business of converting irrigated farmland that was traditionally used to grow marginally profitable feed crops, to greenhouse-equipped farmland used to grow luxury crops with a primary focus on marijuana. Bougainville is an agricultural services company that focuses on providing growers with state-of-the-art computer controlled greenhouses and processing facilities. Bougainville offers fully built out turnkey solutions to licensed I-502 tenant-growers and luxury crop growers who will lease the facilities for production and processing. MCOA does not “touch the plant” and only provides growing infrastructure as a landlord for licensed marijuana growers in the state of Washington. Bougainville has a strong management team with relevant experience and education in place with a focus on build-out and occupancy of its planned greenhouses in Oroville, WA. Strategic plans to expand its land bank, greenhouse campus and I-502 tenant-grower clients are scheduled for expanding operations.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
Communications Contact:
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

INTERVIEW: Tetra Bio-Pharma $TBP.ca Discusses Clinical Study for Smoked #Marijuana #CBD #MMJ $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:21 AM on Friday, November 17th, 2017

Tetra Bio-Pharma is no ordinary Medical Cannabis company. As a true Cannabis Bio-Pharma company, the company is the FIRST and ONLY pharmaceutical company in clinical trials for smoked marijuana, which is currently set to enter the valuable Phase 3 part of the trial.

AGORACOM Sat Down With President, Bernard Fortier To Discuss The Following:

1. How conducting clinical trials is massive differentiator from other companies.
2. The duration of Phase 3
3. The size of the market that will be available upon successful completion of Phase 3
4. How a successful Phase 3 can help solve the opioid crisis
5. Why the Company believes its’ inhalation device will generate $1.5M in revenue for Fiscal 2018
6. The Company’s distribution partnership with Aphria
7. Where the Medical Cannabis industry will be within 5 years

ThreeD Capital Inc. $IDK.ca Acquires Securities of Global Cannabis Applications Corp. $APP.ca $PNP.ca $ZC.ca

Posted by AGORACOM-JC at 10:13 AM on Thursday, November 16th, 2017

Threed capital

  • Acquired ownership and control of an aggregate of 2,000,000 common shares and 2,000,000 common share purchase warrants of Global Cannabis Applications Corp. 
  • Represented approximately 3.7% of all issued and outstanding common shares of Global Cannabis

TORONTO, Nov. 16, 2017 – ThreeD Capital Inc. ( “ThreeD”) (CSE:IDK) is pleased to announce that it has acquired ownership and control of an aggregate of 2,000,000 common shares (the “Subject Shares”) and 2,000,000 common share purchase warrants (the “Subject Warrants” and together with the Subject Shares, the “Subject Units”) of Global Cannabis Applications Corp. (“Global Cannabis”) on November 15, 2017.  The Subject Units represented approximately 3.7% of all issued and outstanding common shares of Global Cannabis as of November 15, 2017 immediately following the transaction described above (or approximately 7.2% on a partially diluted basis, assuming exercise of the Subject Warrants only), resulting in a corresponding increase in the percentage of shares held by ThreeD and its Joint Actor as a result of the transaction.

Immediately before the transaction described above, ThreeD and the Joint Actor held an aggregate of 2,850,000 common shares of the Company (the “Pre-Closing Shares”), representing approximately 5.5% of the issued and outstanding common shares of the Company.  Of this total, ThreeD held an aggregate of 1,000,000 of the Pre-Closing Shares (representing approximately 1.9% of the issued and outstanding common shares of the Company), and the Joint Actor held an aggregate of 1,850,000 of the Pre-Closing Shares (representing approximately 3.6% of the issued and outstanding common shares of the Company).

Immediately following the transaction described above, ThreeD and the Joint Actor held an aggregate of 4,850,000 common shares (the “Post-Closing Shares”) and convertible securities entitling ThreeD and the Joint Actor to acquire an additional 2,000,000 common shares of the Company (the “Post-Closing Convertible Securities”), representing approximately 9.0% of the issued and outstanding common shares of the Company (or approximately 12.3% assuming exercise of such Post-Closing Convertible Securities only).  Of this total, ThreeD held an aggregate of 3,000,000 of the Post-Closing Shares and 2,000,000 of the Post-Closing Convertible Securities (representing approximately 5.6% of the issued and outstanding common shares of the Company, or approximately 9.0% assuming exercise of such Post-Closing Convertible Securities only), and the Joint Actor held an aggregate of 1,850,000 of the Post-Closing Shares and nil of the Post-Closing Convertible Securities (representing approximately 3.4% of the issued and outstanding common shares of the Company).

The Subject Units were acquired in a private placement and not through the facilities of any stock exchange.  The holdings of securities of Global Cannabis by ThreeD and the Joint Actor are managed for investment purposes, and ThreeD and the Joint Actor could increase or decrease their investments in Global Cannabis at any time, or continue to maintain their current investment position, depending on market conditions or any other relevant factor. The aggregate consideration payable for the Subject Units was $200,000, or $0.10 per Subject Unit.

The trade was effected in reliance upon the exemption contained in Section 2.3 of National Instrument 45-106 on the basis that each of ThreeD and the Joint Actor is an “accredited investor” as defined herein.

About ThreeD Capital Inc.

ThreeD Capital Inc. is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources, Artificial Intelligence and Blockchain sectors.

ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services, mentoring and access to the Company’s network in order to earn increases to the Company’s equity stake.

For further information:
Gerry Feldman, CPA, CA
Chief Financial Officer and Corporate Secretary
Feldman@threedcap.com
Phone: 416-606-7655

Tetra Bio-Pharma Inc. $TBP.ca Rx Princeps(TM) Now Available for Patients through Licensed Producer Partner Aphria $APH.ca $AERO $CBDS $CGRW $GBLX

Posted by AGORACOM-JC at 8:23 AM on Thursday, November 16th, 2017

Logo tetrabiopharma rgb web

  • Announced that Rx Princeps™, unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc.

OTTAWA, ONTARIO–(Nov. 16, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps™, unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. (“Aphria”) under Access to Cannabis for Medical Purposes Regulations (ACMPR).

Based on the most recent ACMPR market data from the Government of Canada, it is estimated that the sales of dried medical cannabis in Canada from April 2017 to March 2018 will be over $188M; Tetra is now entering this lucrative market and plans on progressively grabbing a significant share of it over the next two years. Mr Fortier, CEO of Tetra, stated last week “We are expecting to generate around $1.5 million in sales, in fiscal 2018 in our initial launch. Through our promotion and education efforts in Quebec, New Brunswick and part of Ontario, we estimate that over eight thousand patients will start using Rx Princeps™ under prescription from their doctors over in the next twelve months.”

Rx Princeps™ is a new option for doctors who want to prescribe medical cannabis. Prescribing Rx Princeps™ with the Rx Princeps™ inhalation device enables their patients to optimize the benefits of medical cannabis through the intake of a fixed dose of product, thereby ensuring consistency of treatment with a standardized high-quality product.

Aphria grows and produces medical cannabis under a strict quality management program. Tetra chose Aphria as its partner because their production processes were adopted from the highly restricted and regulated pharmaceutical industry, and go above and beyond cannabis industry regulations mandated by Health Canada. As a result, Aphria’s products are in line with the strict quality standards Tetra is establishing for the medical community and its patients.

200,000 patients are already registered under the ACMPR program and around 1.5 million adults in Canada suffer from chronic pain and are considered non-responders to opioids; medical cannabis could be a new therapeutic choice for those patients but physicians need bioavailability and safety data to prescribe medical cannabis with confidence. According to Health Canada, less than 3,000 physicians actually prescribe cannabis to their patients. Tetra is committed to provide them rigorous safety and bioavailability data. Tetra has begun educating pain clinics and the medical profession across Canada on Rx Princeps™, including its advantages for patients.

In Quebec, Tetra is working closely with Sante Cannabis in order to educate patients and support them in their medical journey with cannabis. Sante Cannabis is the first cannabinoid clinic and medical marijuana resource centre in Quebec.

About Rx Princeps™:

Rx Princeps™ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princeps™ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001. Patients who want to purchase Rx Princeps™ in Canada need a prescription from their physicians and to register with Licensed Producer Aphria.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; the success of the Rx Princeps product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com
www.tetrabiopharma.com

Namaste $N.ca Provides Corporate Update on #Cannmart and Namaste MD #MMJ #Marijuana

Posted by AGORACOM-JC at 8:19 AM on Thursday, November 16th, 2017

Nlogo

  • Provides an update on progress with its wholly owned subsidiary, Cannmart Inc.
  • Updated Access to Cannabis for Medical Purposes Regulations application has been submitted to Health Canada, the CannMart facility is now under construction
  • Company expects a six to eight-week time-frame for completion, pending any delays

VANCOUVER, British Columbia, Nov. 16, 2017 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRANKFURT:M5BQ)(OTCMKTS:NXTTF) is pleased to provide an update on progress with its wholly owned subsidiary, Cannmart Inc. (“CannMart”). Management is excited to announce that the updated Access to Cannabis for Medical Purposes Regulations (“ACMPR”) application has been submitted to Health Canada, the CannMart facility is now under construction and the Company expects a six to eight-week time-frame for completion, pending any delays. Namaste’s design goals for the CannMart facility will facilitate the seamless distribution of a wide variety of medicinal cannabis products, which have been sourced both domestically and internationally. Namaste believes that once construction is complete, this state of the art facility will serve as the backbone in servicing Namaste’s impressive and growing database of Canadian medical cannabis consumers.

Further to Namaste’s press release dated November 14, 2017, the application for NamasteMD, the Company’s innovative telemedicine smart-phone app, has been submitted to both the Apple Store and Google for approval, and will available on both IOS and Android devices once approval is received. Additionally, Namaste is pleased to announce that it has engaged multiple doctors and nurse practitioners who will be trained to provide consultations on the NamasteMD app and issue medical documents to Namaste’s patients. NamasteMD has been designed to provide a simple process for patients to connect with a doctor or nurse practitioner through a virtual consultation from the comfort of their home or office. NamasteMD incorporates proprietary identity and age verification technology that will provide high confidence verification for all patients.  Patients who complete their consultation and receive a medical document through NamasteMD may then connect to CannMart’s online portal where they can purchase a wide range of medicinal cannabis products. By utilizing Namaste’s innovative technology of machine-learning algorithms and integrating CannMart on the NamasteMD platform, Namaste strongly believes that it will soon become Canada’s leading online retailer for medicinal cannabis.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “These are extremely exciting times for Namaste as we move forward and implement many new and innovative initiatives. We are very excited about the progress of both CannMart and NamasteMD and believe the next few months will be transformational for the Company. I would like to thank all shareholders for their continued support and in helping Namaste reach these important milestones.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors
“Sean Dollinger”
Chief Executive Officer
+1 (786) 389 9771
Email: Sean@NamasteTechnologies.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

The marijuana market could be (and possibly already is) bigger than the market for beer in Canada $TBP.ca $N.ca

Posted by AGORACOM-JC at 5:20 PM on Thursday, April 13th, 2017

The marijuana market could be (and possibly already is) bigger than the market for beer in Canada

Pot’s retail therapy

TORONTO — It’s a hot, sunny Thursday afternoon on the hard edge of Queen Street West, and the foot traffic at Eden, a pot dispensary, is brisk.

Retailers along this strip of trendy clothing stores, bars, restaurants, shoe shops, tattoo parlours, hairstylists, comic stores and coffee joints cater to the urban hip, and Eden is no different. lnside, iceberg-blue lights illuminate jewel-case cabinets with the product — glass vials of Hindu Kush, El Hefe, Organic Blue Dream — artfully displayed.

On the aquamarine-blue wall at the front are two white iPads, for customers who need quick access to the Internet to check product information.

The place is spotless, sharp. And the air is heavy with the unmistakeable sweet smell of cannabis.

Pot store
The fridge at Eden Medicinal Society, a cannabis retailer in Toronto. (Tyler Anderson / National Post)

Behind the counter, two clerks, a man and a woman both in their 20s, both dressed like their customers, are filling orders, taking cash.

The average transaction, those in the business say, is $50. A pre-rolled joint is $12, but Alicia, the manager, says they won’t start selling a lot of those until the evening, when the university crowd and the kids from the suburbs come downtown.

The afternoonwalk-ins are largely cannabis users who rely on the flowers, ointments, teas, and oils to ease some chronic ailment, or they are creative types — writers, graphics artists, filmmakers — who find extra insight and energy through cannabinoid stimulation. They all have prescriptions from a licensed physician.

The product mix and retail approach at Eden’s downtown store is different than what you will find at the company’s newest outlet a few blocks north near Bayview and Eglinton. There are more seniors and aging baby boomers in that neighbourhood so the store opens earlier and closes earlier.

The Eden outlets are among the 100 or so pot dispensaries in Toronto, but there is easily demand, those in the industry say, for 1,000 such businesses.

They are owned and operated by a mix of campaigners and capitalists.


The campaigners have been working for years to legalize marijuana use. They believe in the huge potential for the drug to manage pain, ease anxiety, and help many to a more productive, happy, creative and healthy existence.

Tania Cyalume and Brandy Zurborg opened their storefront dispensary, Queens of Cannabis, on Bloor Street West just north of Little Italy in February.

Queens of Cannabis owners Tania Cyalume and Brandy Zurborg outside their shop in May 2016. (Maryam Shah / Postmedia Network)

“I guess when you believe in a product, you really believe in it because you’ve seen the way that it affects people,” said Cyalume.

The products Cyalume and Zurborg sell and their approach to retailing match their personal philosophies and lifestyles. Both are vegans, and the edible cannabis products they stock are vegan and  pesticide-free.

Their crusade is about serving patients because they are patients themselves, and use cannabis products regularly to treat their own chronic pain and ailments.

“We’re patients and we believe in it. We also believe that patients have the first right to access before recreational. There is only so much supply, and there is a huge demand,” said Zurborg, who trained as a certified management accountant designation and was  an auditor with the Canada Revenue Agency.

Their goal is not necessarily to get rich. They speak of one day being able to use the proceeds of their retail operation to help fund outreach, at hospices for example, where they can spread the word about the life-changing value of cannabis products.

Marina, who preferred her last name not be used, is a capitalist. She and her husband have had as many as seven dispensaries, some through a franchise model they were trying to build. When she got into the business a few years ago, she approached with a capitalist’s zeal and eye for profit.

The woman has agreed to talk about her industry at an upscale diner set among the forest of steel-and-glass condominium towers where Lake Ontario meets the Toronto suburb of Etobicoke. She arrived in a gleaming white SUV. Petite, direct and energetic, Marina makes no bones about the fact she got into the business to make a pile of cash.

– See more at: http://news.nationalpost.com/features/o-cannabis-retail-therapy#sthash.q9qC3FZy.dpuf

Tetra Bio-Pharma Announces Opening of a New Brunswick Office for Manufacturing & Sales Activities $TBP.ca

Posted by AGORACOM-JC at 4:46 PM on Wednesday, April 12th, 2017

Tbp large

  • Announced today it has opened an office in Moncton, New Brunswick for its manufacturing and sales activities
  • New Brunswick becoming the hub for the Canadian Cannabis industry

OTTAWA, ONTARIO–(April 12, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) announced today it has opened an office in Moncton, New Brunswick for its manufacturing and sales activities. New Brunswick is becoming the hub for the Canadian Cannabis industry.

Tetra is preparing to commercialize several retail products later this year with expected revenues to be generated for the corporation in the fourth quarter. Tetra has already initiated the process to manufacture the first products that act on the cannabinoid system that will be commercialized later this year for sale in Canada and the USA. The Company also intends on commercializing devices (e.g., pipes) for the consumption of medical marijuana in 2017. The Tetra office in Moncton will be responsible to oversee the timely production and launch of the products as well as adhering to the corporation’s budgets.

Tetra has initiated its Phase I clinical trial in March 2017 after manufacturing the PPP001 cannabis drug product at the Ford Pharma contract manufacturing facility in Moncton, New Brunswick. This contract facility developed the proprietary process and equipment required to produce PPP001 pellets and packaging operations. Tetra is also using the contract services of RPC, a New Brunswick provincial crown corporation, to perform its quality control studies to assure that PPP001 conforms to its drug product specifications and quality requirements of a prescription drug.

“We are pleased to announce the opening of a new office in New Brunswick which has become one of the leading provinces in Canada to support the cannabis industry,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “Tetra will manufacture our PPP001 prescription drug as well as additional scheduled products later this year. We are advancing our projects forward which are on time and on budget, a key priority for the Tetra team. We are now one-step closer towards our goal of commercialization in bringing our innovative cannabis based products to market.”

“We acted quickly to prepare for the development of this industry in New Brunswick,” said Stephen Lund, CEO of Opportunities NB. “The addition of Tetra Bio-Pharma to the province is welcomed news. We have the research, education and production facilities in place for companies to be successful in this rapidly growing industry.”

According to Dr. Guy Chamberland, CSO at Tetra Bio-Pharma Inc., “The use of the facility in Moncton allows Tetra to manufacture the PPP001 drug product for the clinical trial according to the corporation’s timelines and budget. The RPC research and technology organization provides Tetra with the high-level expertise required for assessing the quality aspects of PPP001 while keeping the costs associated with these activities within budget due to RPC not-for-profit status. I can report that the Phase 1 trial is advancing on schedule and according to the corporation’s plans we expect to complete the Phase Ia portion of the study by mid-May. The results of the Phase Ia will provide TBP with a strategic understanding of the commercial potential of marijuana products and allow the corporation to complete its Phase II and III trial plans.”

About Tetra Bio Pharma:
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTCQX:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(343) 689-0714

END OF DAY ALERT: (TBP: CSE) UP 38% ON 4.3M SHARES TRADED!

Posted by AGORACOM-JC at 5:05 PM on Monday, February 13th, 2017

TRADING ALERT!!!

TBP: CSE UP 38% ON 4.3M SHARES TRADED!

Tbp large

Close: $0.79 Up: $0.22

Percentage: +38% Volume: 4.3M Shares

Hub On AGORACOM